The Research Group .
Welcome,         Profile    Billing    Logout  
 7 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nguyen, Van Vinh Chau
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT05611710: Anakinra in Dengue With Hyperinflammation ( AnaDen )

Recruiting
2
160
RoW
Placebo, Anakinra
Oxford University Clinical Research Unit, Vietnam, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, Wellcome Trust
Dengue, Dengue With Warning Signs, Severe Dengue, Anakinra, Immuno-modulation, Anti-inflammatory Agents, Macrophage Activation Syndrome, Hyperinflammatory Syndrome, Cytokine Storm
12/25
12/27
CA209-587, NCT04204837 / 2016-002811-16: Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

Recruiting
2
61
Europe
Nivolumab, Nivolumab plus Relatlimab
Salzburger Landeskliniken, Bristol-Myers Squibb
Squamous Cell Carcinoma of the Skin
12/26
12/27
NCT06228976: Mindfulness-based, Mobile Health (mHealth) Smoking Cessation Intervention in Vietnam

Recruiting
N/A
1200
RoW
Mindfulness-based, smoking cessation focused text messages., Educational messages, Control messages
Hanoi University of Public Health, Georgia State University, National Institutes of Health (NIH), Fogarty International Center of the National Institute of Health
Smoking Cessation, Mindfulness, Telemedicine, Smoking
08/24
12/24
Khan, Mohammed
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
PREVENT-PVR, NCT04580147: Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

Recruiting
2
150
US
Intravitreal aflibercept injection, Intravitreal Eylea injection, Sham control
M. Ali Khan, MD, Southeastern Retina Associates, Eye Associates of New Mexico, University of California, Los Angeles
Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
09/23
12/23
NCT04645758: A Study to Analyse the Immediate Effect of Dry Needling and Extra Corporeal Shock Wave Therapy on Hand Grip Strength

Recruiting
N/A
27
RoW
Dry needling and Extra corporeal Shock wave therapy, Dry needle/Acupuncture needle.Shock wave therapy
Comprehensive Rehabilitation Centre, Medina, Saudi Arabia
Muscle Weakness Condition
11/20
11/20
NCT06643676: Effect of Targeted Endodontic Microsurgery on Quality of Life and Healing on Mandibular Molars

Recruiting
N/A
50
RoW
Targeted Endodontic Microsurgery Using 3d Printed surgical guide using the patient's CBCT data, periapical surgery, Targeted Endodontic Microsurgery, Guided Endodontic Microsurgery, apicoectomy, Conventional Endodontic Microsurgery with a free hand procedure using bur and CBCT analysis
Postgraduate Institute of Dental Sciences Rohtak
Periapical Diseases, Periapical Periodontitis, Periapical Cyst, Periapical Granuloma, Periapical Pathology, Endodontic Microsurgery, Targeted Endodontic Microsurgery
12/25
12/25
NCT04098146: Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection

Recruiting
N/A
300
Europe, US
Surgical Resection and Reconstruction
AO Innovation Translation Center
Mandibular Reconstruction, Segmental Mandibular Defects
06/30
12/30
Lerman, Sam
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NA-PAS, NCT04836546: Eversense® Non-adjunctive Use Post Approval Study

Recruiting
N/A
925
US
Blood glucose meter, Eversense CGM System
Senseonics, Inc.
Diabetes
03/26
03/26
Tallet, Christine
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Albornoz, Martin
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29

Download Options